Management of intrahepatic cholangiocarcinoma: a review for clinicians

Keyphrases

• Intrahepatic Cholangiocarcinoma (iCCA) 100%
• Liver Transplantation 28%
• Treatment Options 28%
• Neoadjuvant Therapy 28%
• Tumor 14%
• Clinical Practice 14%
• Liver 14%
• Hepatocellular Carcinoma 14%
• Survival Rate 14%
• Medical Treatment 14%
• Chronic Liver Disease 14%
• Adjuvant Therapy 14%
• Surgical Treatment 14%
• Cirrhotic Liver 14%
• Risk Factors 14%
• Treatment Survival 14%
• Postoperative Morbidity 14%
• Sustained Response 14%
• Surgical Approach 14%
• Genetic Profile 14%
• Drug Therapy 14%
• Regenerative Process 14%
• Checkpoint Inhibitors 14%
• Molecular Targets 14%
• Resectability 14%
• Survival Outcomes 14%
• Curative Treatment 14%
• Biliary Epithelial Cells 14%
• Liver Malignancy 14%
• Locoregional Therapy 14%
• Future Liver Remnant 14%
• Major Hepatectomy 14%
• Remnant Liver Volume 14%
• R0 Liver Resection 14%
• Extent of Lymphadenectomy 14%
• Advanced Tumors 14%
• Patient numbers 14%

Medicine and Dentistry

• Clinician 100%
• Cholangiocarcinoma 100%
• Liver Transplantation 28%
• Hepatectomy 28%
• Neoadjuvant Therapy 28%
• Tumor 28%
• Treatment Option 28%
• Drug Therapy 14%
• Chronic Liver Disease 14%
• Hepatocellular Carcinoma 14%
• Survival Rate 14%
• Retroperitoneal Lymph Node Dissection 14%
• Adjuvant Therapy 14%
• Cancer 14%
• Epithelial Cell 14%
• Surgical Approach 14%
• Morbidity 14%
• Genetics 14%